PMID- 22172874
OWN - NLM
STAT- MEDLINE
DCOM- 20120329
LR  - 20111216
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 43
IP  - 10
DP  - 2011 Dec
TI  - Immunoglobulin prophylaxis against cytomegalovirus infection in patients at high 
      risk of infection following allogeneic hematopoietic cell transplantation.
PG  - 3927-32
LID - 10.1016/j.transproceed.2011.08.104 [doi]
AB  - Reports on the efficacy of intravenous immunoglobulin (IVIG) prophylaxis against 
      cytomegalovirus (CMV) infection after allogeneic hematopoietic cell 
      transplantation (HCT) have often sparked controversy. In addition, we are not 
      aware of any study that has examined whether prophylaxis with IVIG affects the 
      incidence of CMV infection in high-risk patients--those who are elderly or have 
      received human leukocyte antigen (HLA) mismatched HCT. In the present open-label, 
      phase II study, we addressed this question. We enrolled 106 patients in the 
      study. The cumulative incidences of CMV infection at 100 days after HCT were 
      similar in the intervention and the control groups (68% and 64%, P=.89; 89% and 
      87%, P=.79, respectively, for patients 55 years or older and those who received 
      HLA-mismatched HCT). In those who received HLA-mismatched HCT, 1-year overall 
      survival after HCT was 46% in the intervention group and 40% in the control group 
      (P=.31); for age>/=55 years, the corresponding values were 46% and 40% (P=.27). Our 
      data showed that prophylaxis with regular polyvalent IVIG did not affect the 
      incidence of CMV infections or survival among older patients or those who receive 
      HLA-mismatched HCT.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Ichihara, H
AU  - Ichihara H
AD  - Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
FAU - Nakamae, H
AU  - Nakamae H
FAU - Hirose, A
AU  - Hirose A
FAU - Nakane, T
AU  - Nakane T
FAU - Koh, H
AU  - Koh H
FAU - Hayashi, Y
AU  - Hayashi Y
FAU - Nishimoto, M
AU  - Nishimoto M
FAU - Nakamae, M
AU  - Nakamae M
FAU - Yoshida, M
AU  - Yoshida M
FAU - Bingo, M
AU  - Bingo M
FAU - Okamura, H
AU  - Okamura H
FAU - Aimoto, M
AU  - Aimoto M
FAU - Manabe, M
AU  - Manabe M
FAU - Hagihara, K
AU  - Hagihara K
FAU - Terada, Y
AU  - Terada Y
FAU - Nakao, Y
AU  - Nakao Y
FAU - Hino, M
AU  - Hino M
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Analysis of Variance
MH  - Chi-Square Distribution
MH  - Cytomegalovirus Infections/immunology/mortality/*prevention & control/virology
MH  - Female
MH  - HLA Antigens/immunology
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects/mortality
MH  - Histocompatibility
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Immunologic Factors/*administration & dosage
MH  - Incidence
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
MH  - Survival Analysis
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/12/17 06:00
MHDA- 2012/03/30 06:00
CRDT- 2011/12/17 06:00
PHST- 2011/05/13 00:00 [received]
PHST- 2011/08/15 00:00 [revised]
PHST- 2011/08/31 00:00 [accepted]
PHST- 2011/12/17 06:00 [entrez]
PHST- 2011/12/17 06:00 [pubmed]
PHST- 2012/03/30 06:00 [medline]
AID - S0041-1345(11)01286-3 [pii]
AID - 10.1016/j.transproceed.2011.08.104 [doi]
PST - ppublish
SO  - Transplant Proc. 2011 Dec;43(10):3927-32. doi: 
      10.1016/j.transproceed.2011.08.104.